“Results came in within our expectations. Revenue and net profit were 4.2% and 6.9% higher than our forecast, respectively,” write Ng and Chan in their Mar 10 report.
Following the release of Hyphens Pharma’s FY2024 ended Dec 31, 2024 results, SAC Capital analysts Daniel Ng and Matthias Chan are keeping their “buy” call on the pharmaceutical company at a raised target price (TP) of 46 cents from 38 cents previously.
The analysts’ upward revision is primarily driven by higher price-to-earnings ratio (P/E) multiples of comparable companies, reflecting stronger market confidence in the sector.
